Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21st
February 19, 2024
Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients
March 23, 2023
Related Post
-
-
Biotricity Advances Towards Breakeven Milestone – Set to Announce Record Margins and Operational Efficiency for Third Quarter of Fiscal Year 2024
February 14, 2024
-
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
February 14, 2024
-
PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE WESTERN VETERINARY CONFERENCE IN LAS VEGAS, NEVADA
February 13, 2024